US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
HUTCHMED China Limited (HCM)
HUTCHMED China Limited (HCM) ニュース

HCM

HUTCHMED China (HCM)

HUTCHMED China Limited

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:HCM

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/09/26	21 : 51	GlobeNewswire Inc.	Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing	NASDAQ:HCM	HUTCHMED China Limited
2024/09/24	19 : 09	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/09/24	16 : 00	GlobeNewswire Inc.	HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda	NASDAQ:HCM	HUTCHMED China Limited
2024/09/18	00 : 22	GlobeNewswire Inc.	International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024	NASDAQ:HCM	HUTCHMED China Limited
2024/09/09	09 : 00	GlobeNewswire Inc.	HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer	NASDAQ:HCM	HUTCHMED China Limited
2024/08/30	19 : 13	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/08/30	13 : 30	GlobeNewswire Inc.	HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China	NASDAQ:HCM	HUTCHMED China Limited
2024/08/22	19 : 10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/08/21	19 : 07	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/08/21	17 : 30	GlobeNewswire Inc.	HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia	NASDAQ:HCM	HUTCHMED China Limited
2024/07/31	20 : 13	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/07/31	20 : 00	GlobeNewswire Inc.	HUTCHMED Reports 2024 Interim Results and Provides Business Updates	NASDAQ:HCM	HUTCHMED China Limited
2024/07/04	09 : 00	GlobeNewswire Inc.	HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status	NASDAQ:HCM	HUTCHMED China Limited
2024/06/26	17 : 30	GlobeNewswire Inc.	HUTCHMED to Announce 2024 Half-Year Financial Results	NASDAQ:HCM	HUTCHMED China Limited
2024/06/24	18 : 30	GlobeNewswire Inc.	Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024	NASDAQ:HCM	HUTCHMED China Limited
2024/06/22	05 : 00	GlobeNewswire Inc.	HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda	NASDAQ:HCM	HUTCHMED China Limited
2024/06/17	09 : 00	GlobeNewswire Inc.	HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology	NASDAQ:HCM	HUTCHMED China Limited
2024/06/07	19 : 25	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/06/07	09 : 00	GlobeNewswire Inc.	HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China	NASDAQ:HCM	HUTCHMED China Limited
2024/06/03	19 : 13	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/06/03	09 : 00	GlobeNewswire Inc.	HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine	NASDAQ:HCM	HUTCHMED China Limited
2024/05/31	19 : 12	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/05/24	19 : 06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/05/24	09 : 00	GlobeNewswire Inc.	HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting	NASDAQ:HCM	HUTCHMED China Limited
2024/05/17	23 : 02	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/05/17	23 : 00	GlobeNewswire Inc.	HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees	NASDAQ:HCM	HUTCHMED China Limited
2024/05/17	09 : 00	GlobeNewswire Inc.	HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress	NASDAQ:HCM	HUTCHMED China Limited
2024/05/14	09 : 00	GlobeNewswire Inc.	HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui	NASDAQ:HCM	HUTCHMED China Limited
2024/05/14	09 : 00	GlobeNewswire Inc.	HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China	NASDAQ:HCM	HUTCHMED China Limited
2024/05/08	17 : 30	GlobeNewswire Inc.	HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee	NASDAQ:HCM	HUTCHMED China Limited

Showing the most relevant articles for your search:NASDAQ:HCM

1 2 3 4 5 6 7 8 9 10 次へ >>

JP Morgan Chase

Verizon Communications

American Express

Gold vs US Dollar

Health Care Select Sector

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約